


**AMENDMENTS TO THE CLAIMS**


**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (original): A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:



(wherein the cyclic amino group is represented by the following formula [II]):



in which the cyclic amino group is a 3- to 8-membered saturated cyclic amine or a 3- to 8-membered saturated cyclic amine bridged with C<sub>1-5</sub>alkylene or C<sub>1-4</sub>alkylene-O-C<sub>1-4</sub>alkylene between any different two carbon atoms of the cyclic amine, which cyclic amine is substituted

with a group represented by  $-(CR^1R^2)_m-(CHR^3)_n-X$ ,  $R^4$  and  $R^5$  independently on the same or different carbon atoms of the cyclic amine;

X is cyano, hydroxy,  $-CO_2R^8$  or  $-CONR^9R^{10}$ ;

Y is N or  $CR^{11}$ ;

$R^1$  is hydrogen, hydroxy,  $C_{1-5}$ alkyl,  $C_{1-5}$ alkoxy- $C_{1-5}$ alkyl or hydroxy- $C_{1-5}$ alkyl;

$R^2$  is hydrogen or  $C_{1-5}$ alkyl;

$R^3$  is hydrogen, cyano,  $C_{1-5}$ alkyl,  $C_{1-5}$ alkoxy- $C_{1-5}$ alkyl or hydroxy- $C_{1-5}$ alkyl;

m is an integer selected from 0, 1, 2, 3, 4 and 5;

n is 0 or 1;

$R^4$  is hydrogen, hydroxy, hydroxy- $C_{1-5}$ alkyl, cyano, cyano- $C_{1-5}$ alkyl or  $C_{1-5}$ alkyl;

$R^5$  is hydrogen or  $C_{1-5}$ alkyl;

$R^6$  is hydrogen,  $C_{1-5}$ alkyl,  $C_{3-8}$ cycloalkyl,  $C_{3-8}$ cycloalkyl- $C_{1-5}$ alkyl, hydroxy,  $C_{1-5}$ alkoxy,  $C_{3-8}$ cycloalkyloxy, halogen,  $C_{1-5}$ alkylthio or  $-N(R^{12})R^{13}$ ;

$R^7$  is hydrogen, halogen,  $C_{1-5}$ alkyl,  $C_{3-8}$ cycloalkyl,  $C_{3-8}$ cycloalkyl- $C_{1-5}$ alkyl, hydroxy,  $C_{1-5}$ alkoxy,  $C_{3-8}$ cycloalkyloxy,  $-N(R^{14})R^{15}$ ,  $-CO_2R^{16}$ ,  $-CON(R^{17})R^{18}$ , cyano, nitro,  $C_{1-5}$ alkylthio, trifluoromethyl or trifluoromethoxy;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen,  $C_{1-5}$ alkyl,  $C_{3-8}$ cycloalkyl,  $C_{2-5}$ alkenyl,  $C_{2-5}$ alkynyl,  $C_{1-5}$ alkoxy,  $C_{1-5}$ alkylthio,  $C_{1-5}$ alkylsulfinyl,  $C_{1-5}$ alkylsulfonyl, cyano, nitro, hydroxy,  $-CO_2R^{19}$ ,  $-C(=O)R^{20}$ ,  $-CONR^{21}R^{22}$ , -

$\text{OC(=O)R}^{23}$ ,  $-\text{NR}^{24}\text{CO}_2\text{R}^{25}$ ,  $-\text{S(=O)}_r\text{NR}^{26}\text{R}^{27}$ , trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy, methylenedioxy, ethylenedioxy and  $-\text{N(R}^{28})\text{R}^{29}$ ;

$\text{R}^8$  is hydrogen,  $\text{C}_{1-10}\text{alkyl}$ ,  $\text{C}_{3-8}\text{cycloalkyl}$ ,  $\text{C}_{3-8}\text{cycloalkyl-C}_{1-5}\text{alkyl}$ , aryl or aryl- $\text{C}_{1-5}\text{alkyl}$ ;

$\text{R}^9$  and  $\text{R}^{10}$  are the same or different, and independently are hydrogen,  $\text{C}_{1-5}\text{alkyl}$ ,  $\text{C}_{3-8}\text{cycloalkyl}$ ,  $\text{C}_{3-8}\text{cycloalkyl-C}_{1-5}\text{alkyl}$ , aryl or aryl- $\text{C}_{1-5}\text{alkyl}$ ; or  $\text{R}^9$  and  $\text{R}^{10}$  form a ring selected from saturated 3 to 8 membered ring with the attached nitrogen atom, wherein one of the carbon atoms of such saturated 3 to 8 membered ring is optionally replaced by an oxygen or sulfur atom or by N-Z wherein Z is hydrogen, benzyl or  $\text{C}_{1-5}\text{alkyl}$ ;

$\text{R}^{11}$  is hydrogen, halogen or  $\text{C}_{1-5}\text{alkyl}$ ;

$\text{R}^{12}$ ,  $\text{R}^{13}$ ,  $\text{R}^{14}$  and  $\text{R}^{15}$  are the same or different, and independently are hydrogen or  $\text{C}_{1-5}\text{alkyl}$ ;


$\text{R}^{16}$ ,  $\text{R}^{19}$  and  $\text{R}^{25}$  are the same or different, and independently are hydrogen or  $\text{C}_{1-5}\text{alkyl}$ ,  $\text{C}_{3-8}\text{cycloalkyl}$ ,  $\text{C}_{3-8}\text{cycloalkyl-C}_{1-5}\text{alkyl}$ , aryl or aryl- $\text{C}_{1-5}\text{alkyl}$ ;

$\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{20}$ ,  $\text{R}^{21}$ ,  $\text{R}^{22}$ ,  $\text{R}^{23}$ ,  $\text{R}^{24}$ ,  $\text{R}^{26}$ ,  $\text{R}^{27}$ ,  $\text{R}^{28}$  and  $\text{R}^{29}$  are the same or different, and independently are hydrogen,  $\text{C}_{1-5}\text{alkyl}$  or  $\text{C}_{3-8}\text{cycloalkyl}$ ;

r is 1 or 2)

, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, pharmaceutically acceptable prodrugs thereof or pharmaceutically acceptable salts and hydrates thereof.

2. (original): The thienopyrimidine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [III]:



(wherein X, m, n, the cyclic amino group, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

3. (original): The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3; R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>6</sup> is C<sub>1-5</sub>alkyl; R<sup>7</sup> is hydrogen or C<sub>1-5</sub>alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylthio, trifluoromethyl, trifluoromethoxy and -N(R<sup>28</sup>)R<sup>29</sup> (wherein R<sup>28</sup> and R<sup>29</sup> are the same or different, and independently are hydrogen or C<sub>1-3</sub>alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

4. (original): The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is cyano; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is 0 or 1;  $R^1$ ,  $R^2$ ,  $R^4$  and  $R^5$  are hydrogen;  $R^6$  is  $C_{1-5}$ alkyl;  $R^7$  is hydrogen or  $C_{1-5}$ alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and  $C_{1-3}$ alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

5. (original): The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3;  $R^1$ ,  $R^2$ ,  $R^4$  and  $R^5$  are hydrogen;  $R^6$  is  $C_{1-5}$ alkyl;  $R^7$  is hydrogen or  $C_{1-5}$ alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen,  $C_{1-3}$ alkyl,  $C_{1-3}$ alkoxy,  $C_{1-3}$ alkylthio, trifluoromethyl, trifluoromethoxy and  $-N(R^{28})R^{29}$  (wherein  $R^{28}$  and  $R^{29}$  are the same or different, and independently are hydrogen or  $C_{1-3}$ alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

6. (original): The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is hydroxy; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3;  $R^1$ ,  $R^2$ ,  $R^4$  and


$R^5$  are hydrogen;  $R^6$  is  $C_{1-5}$ alkyl;  $R^7$  is hydrogen or  $C_{1-5}$ alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and  $C_{1-3}$ alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

7. (original): The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is  $-\text{CO}_2\text{R}^8$  or  $-\text{CONR}^9\text{R}^{10}$ ; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3;  $R^1$ ,  $R^2$ ,  $R^4$  and  $R^5$  are hydrogen;  $R^6$  is  $C_{1-5}$ alkyl;  $R^7$  is hydrogen or  $C_{1-5}$ alkyl;  $R^8$  is hydrogen or  $C_{1-10}$ alkyl;  $R^9$  and  $R^{10}$  are the same or different, and independently are hydrogen or  $C_{1-5}$ alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen,  $C_{1-3}$ alkyl,  $C_{1-3}$ alkoxy,  $C_{1-3}$ alkylthio, trifluoromethyl, trifluoromethoxy and  $-\text{N}(\text{R}^{28})\text{R}^{29}$  (wherein  $\text{R}^{28}$  and  $\text{R}^{29}$  are the same or different, and independently are hydrogen or  $C_{1-3}$ alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

8. (original): The thienopyrimidine derivative substituted with the cyclic amino group according to claim 2 represented by formula [III], wherein X is  $-\text{CO}_2\text{R}^8$  or  $-\text{CONR}^9\text{R}^{10}$ ; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3;  $R^1$ ,  $R^2$ ,  $R^4$  and  $R^5$  are hydrogen;  $R^6$  is  $C_{1-5}$ alkyl;  $R^7$  is hydrogen or  $C_{1-5}$ alkyl;  $R^8$  is hydrogen or  $C_{1-}$

$_{10}$ alkyl;  $R^9$  and  $R^{10}$  are the same or different, and independently are hydrogen or  $C_{1-5}$ alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and  $C_{1-3}$ alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

9. (original): The thienopyridine derivative substituted with the cyclic amino group according to claim 1 represented by the following formula [IV]:



(wherein X, m, n, the cyclic amino group,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^{11}$  and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

10. (original): The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is cyano; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3;  $R^1$ ,  $R^2$ ,  $R^4$  and  $R^5$  are hydrogen;  $R^6$  is  $C_{1-5}$ alkyl;  $R^7$  is hydrogen or  $C_{1-5}$ alkyl;  $R^{11}$  is hydrogen or  $C_{1-5}$ alkyl; and Ar

is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylthio, trifluoromethyl, trifluoromethoxy and -N(R<sup>28</sup>)R<sup>29</sup> (wherein R<sup>28</sup> and R<sup>29</sup> are the same or different, and independently are hydrogen or C<sub>1-3</sub>alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

11. (original): The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is cyano; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is 0 or 1; R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>6</sup> is C<sub>1-5</sub>alkyl; R<sup>7</sup> is hydrogen or C<sub>1-5</sub>alkyl; R<sup>11</sup> is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C<sub>1-3</sub>alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

12. (original): The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is hydroxy; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>6</sup> is C<sub>1-5</sub>alkyl; R<sup>7</sup> is hydrogen or C<sub>1-5</sub>alkyl; R<sup>11</sup> is hydrogen or C<sub>1-5</sub>alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylthio, trifluoromethyl, trifluoromethoxy and -N(R<sup>28</sup>)R<sup>29</sup> (wherein R<sup>28</sup> and R<sup>29</sup> are the same or different,



and independently are hydrogen or C<sub>1-3</sub>alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

13. (original): The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is hydroxy; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 1, 2 and 3; R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>6</sup> is C<sub>1-5</sub>alkyl; R<sup>7</sup> is hydrogen or C<sub>1-5</sub>alkyl; R<sup>11</sup> is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C<sub>1-3</sub>alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

14. (original): The thienopyridine derivative substituted with the cyclic amino group according to claim 9 represented by formula [IV], wherein X is -CO<sub>2</sub>R<sup>8</sup> or -CONR<sup>9</sup>R<sup>10</sup>; the cyclic amino group is a 4- to 7-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3; R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen; R<sup>6</sup> is C<sub>1-5</sub>alkyl; R<sup>7</sup> is hydrogen or C<sub>1-5</sub>alkyl; R<sup>8</sup> is hydrogen or C<sub>1-10</sub>alkyl; R<sup>9</sup> and R<sup>10</sup> are the same or different, and independently are hydrogen or C<sub>1-5</sub>alkyl; R<sup>11</sup> is hydrogen or C<sub>1-5</sub>alkyl; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylthio, trifluoromethyl, trifluoromethoxy and -N(R<sup>28</sup>)R<sup>29</sup> (wherein R<sup>28</sup> and R<sup>29</sup> are the same or different, and independently are hydrogen or C<sub>1-3</sub>alkyl), individual

isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

15. (original): The thienopyridine derivative substituted with the cyclic amino group according to claim 2 represented by formula [IV], wherein X is  $-\text{CO}_2\text{R}^8$  or  $-\text{CONR}^9\text{R}^{10}$ ; the cyclic amino group is a 6-membered saturated cyclic amine; n is 0; m is an integer selected from 0, 1, 2 and 3;  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^4$  and  $\text{R}^5$  are hydrogen;  $\text{R}^6$  is  $\text{C}_{1-5}$ alkyl;  $\text{R}^7$  is hydrogen or  $\text{C}_{1-5}$ alkyl;  $\text{R}^8$  is hydrogen or  $\text{C}_{1-10}$ alkyl;  $\text{R}^9$  and  $\text{R}^{10}$  are the same or different, and independently are hydrogen or  $\text{C}_{1-5}$ alkyl;  $\text{R}^{11}$  is hydrogen; and Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and  $\text{C}_{1-3}$ alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

16. (original): Compounds represented by formula [I] according to claim 1, which compounds are selected from the group consisting of

{1-[7-(4-Bromo-2,6-dimethyl-phenyl)-2-methyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-methanol,

{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-methanol,

2-{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-piperidin-4-yl}-ethanol,

{1-[7-(4-bromo-2,6-dimethyl-phenyl)-2,6-dimethyl-thieno[3,2-d]pyrimidin-4-yl]-  
piperidin-4-yl}-acetonitrile,

{1-[3-(2,4-dichloro-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-  
methanol,

{1-[5-methyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-  
yl}-methanol,

{1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-  
piperidin-4-yl}-methanol,

{1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-  
piperidin-4-yl}-methanol,

{1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-  
methanol,

{1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-  
yl}-methanol,

2-{1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-  
piperidin-4-yl}-ethanol,

2-{1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-  
piperidin-4-yl}-ethanol,

2-{1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-  
yl}-ethanol,

2-{1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-ethanol,

1-[5-methyl-3-(2,4,6-trimethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidine-3-carbonitrile,

{1-[3-(4-bromo-2,6-dimethyl-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile,

{1-[3-(4-bromo-2,6-dimethyl-phenyl)-2,5-dimethyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile,

{1-[3-(2,4-dibromo-phenyl)-5-methyl-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile

and {1-[5-methyl-3-(2,4,6-trichloro-phenyl)-thieno[3,2-b]pyridin-7-yl]-piperidin-4-yl}-acetonitrile.

17. (currently amended): An antagonist for CRF receptors, comprising a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1 ~~any one of claims 1 to 16~~, as an active ingredient.

18. (currently amended): Use of a thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group, a pharmaceutically acceptable salt thereof or its hydrate according to claim

Preliminary Amendment  
Appln. No.: National Stage of PCT/JP2005/000318

~~any one of claim 1 to 16~~, for the manufacture of a therapeutic agent as an antagonist for CRF  
receptors.